Причины и пути снижения выраженности острофазовой реакции при лечении остеопороза внутривенными бисфосфонатами (обзор литературы)

1. Лесняк О.М. Аудит состояния проблемы остеопороза в Российской Федерации. Профилактическая медицина. 2011;14(2):7–10.

2. Lesnyak O., Ershova O., Belova K., et al. Epidemiology of fracture in the Russian Federation and the development of a FRAX model. Arch Osteoporos. 2012;7(1–2):67–73. Doi: 10.1007/s11657-012-0082-3.

3. Белая Ж.Е., Белова К.Ю., Бирюкова Е.В. и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Остеопороз и остеопатии. 2021;24(2):4–47.

4. Khosla S., Shane E. A Crisis in the Treatment of Osteoporosis. J Bone Miner Res. 2016;31(8):1485–87. Doi: 10.1002/jbmr.2888.

5. Li C., Lu K., Shi Q., Gong Y.Q. Predicting the individualized risk of nonadherence to zoledronic acid among osteoporosis patients receiving the first infusion of zoledronic acid: development and validation of new predictive nomograms. Ther Adv Chronic Dis. 2022;30;13:20406223221114214. Doi: 10.1177/20406223221114214.

6. Reid I.R., Gamble G.D., Mesenbrink P., Lakatos P. and Black D.M. Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid. Clin Endocrinol Metab. 2010;95:4380–87. Doi: 10.1210/jc.2010-0597.

7. Dicuonzo G., Vincenzi B., Santini D., et al. Fever after zoledronic acid administration is due to increase in TNF-α and IL-6. J Interferon Cytokine Res. 2003; 23(11):649–54. Doi: 10.1089/107999003322558782.

8. Лесняк О.М., Аношенкова О.Н., Барбарин И.Н. и др. Результаты двухлетнего открытого многоцентрового наблюдательного исследования эффективности, безопасности, переносимости и влияния на качество жизни. Лечащий врач. 2018;3:9–18.

9. Black D.M., Delmas P.D., Eastell R., et al. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–22. Doi: 10.1056/NEJMoa067312.

10. Шафиева И.А., Булгакова С.В., Шафиева А.В. Оценка переносимости препаратов золедроновой кислоты для парентерального введения. Медицинский совет. 2022;(11):96–101.

11. Wark J.D., Bensen W., Recknor C., et al. Treatment with acetaminophen/ paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporos Int. 2012;23(2):503–12. Doi: 10.1007/s00198-011-1563-8.

12. Sieber P., Lardelli P., Kraenzlin C.A., et al. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice. Clin Drug Investig. 2013;33(2):117–22. Doi: 10.1007/s40261-012-0041-1.

13. Bock O., Boerst H., Thomasius F.E., et al. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact. 2007;7(2):144–48.

14. Аnastasilakis A.D., Polyzos S.A., Makras P., et al. Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. Bone. 2012;50(5):1130–34. Doi: 10.1016/j.bone.2012.02.006.

15. Popp A., Senn R., Curkovic I., et al. Factors associated with acute-phase response of bisphosphonate-naive or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate. Osteoporos Int. 2017;28(6):1995–2002. Doi: 10.1007/s00198-017-3992-5.

16. Billington E.O., Horne A., Gamble G.D., et al. Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial. Osteoporos Int. 2017;28:1867–74. Doi: 10.1007/s00198-017-3960-0.

17. Smrecnik M., Kavcic Trsinar Z., Kocjan T. Adrenal crisis after first infusion of zoledronic acid: a case report. Osteoporos Int. 2018;29(7):1675-78. Doi: 10.1007/s00198-018-4508-7.

18. Makras P., Anastasilakis A.D., Polyzos S.A.,et al. No effect of rosuvastatin in the zoledronateinduced acute-phase response. Calcif Tissue Int. 2011;88(5): 402–8. Doi: 10.1016/j.bonr.2021.101128.

19. Srivastava T., Haney C.J., Alon U.S. Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion. J Bone Miner Res. 2009;24(2):334–37. Doi: 10.1359/jbmr.081016.

20. Thompson K., Keech F., McLernon D.J., Vinod K., et al. Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women. Bone. 2011;49(1):140–45. Doi: 10.1016/j.bone.2010.10.177.

21. Wang H., Hu Z.H., Chen L., Pan Y. Influence of history of oral bisphosphonates on the incidence rate of fever after intravenous injection of zoledronic acid in patients with osteoporosis. Beijing Da Xue Xue Bao Yi Xue Ban. 2016;48(4):680–82.

22. Deng J.M., Cai D.M., Jie S.M., et al. Sequential Treatment Reduces the Acute Phases of Adverse Effect of Zoledronic Acid in First Time Users. Open Journal of Preventive Medicine. 2018;08(07):189–205. Doi: 10.4236/ojpm.2018.87018.

23. Chiara C., Watts N.B., De Santis M., et al. Acute phase reactions after zoledronic acid infusion: protective role of 25-hydroxyvitamin D and previos oral bisphosphonate therapy. Endocrine Practice. 2018;24(5):405–10. Doi: 10.4158/EP161638.

24. Lu K., Shi Q., Gong Y.Q., Li C. Association between vitamin D and zoledronate-induced acute-phase response fever risk in osteoporotic patients. Front Endocrinol (Lausanne). 2022;10;13:991913. Doi: 10.3389/fendo.2022.991913.

25. Bertoldo F, Pancheri S, Zenari S, et al. Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res. 2010;25(3):447–54. Doi: 10.1359/jbmr.090819.

26. Tsurukami H. Acute phase reaction following bisphosphonates. Clin Calcium. 2017;27(2):213–23.

27. Black D.M., Reid I.R., Napoli N., et al. The interaction of acute-phase reaction and efficacy for osteoporosis after zoledronic acid: HORIZON pivotal fracture trial J Bone Miner Res. 2021;37(1):21–8. Doi:10.1002/jbmr.4434.